We have a responsibility as a leading global healthcare company to do all we can to address this urgent unmet medical need.
Developing effective Ebola vaccines will be critical if we are to combat outbreaks of this disease and protect frontline healthcare workers as well as the families and friends of Ebola victims.
We recognize the urgency of the situation and the need to collaborate with multiple partners to develop preventive solutions for Ebola.
While recognizing this is an investigational vaccine still in development, we have taken pandemic preparedness steps with the goal of ensuring that the world is better equipped for Ebola outbreaks.
The investigational preventive Ebola vaccine regimen in development at the Janssen Pharmaceutical Companies of Johnson & Johnson:
Johnson & Johnson has built a stockpile of up to 1.5 million investigational Ebola vaccine regimens for potential use in public health emergencies.
Janssen begins Ebola vaccine research program with NIH support
· West Africa Ebola outbreak begins; declared international health emergency
· J&J commits to accelerate development and expand production of an Ebola vaccine
Second-largest Ebola outbreak begins in DRC
50,000 people have been vaccinated with Janssen’s Ebola vaccine to date
European Commission (EC) grants Marketing Authorisation for the Janssen Ebola vaccine regimen for the prevention of Ebola Virus Disease.
Johnson & Johnson has made a significant investment in the Janssen Ebola vaccine development program. We have also forged strategic partnerships with a wide range of the world’s leading scientific and medical research organizations to accelerate our progress.
Through our Janssen Pharmaceutical Companies, we are developing new vaccines and/or treatments to combat infectious diseases that: